Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat or sildenafil for congenital nephrogenic diabetes insipidus
2016-001591-30Phase 2Completed
- Sponsor
- University Hospital Odense
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of riociguat and sildenafil in congenital arginine vasopressin resistance (cAVP-R) (2 arms), sponsored by University Hospital Odense. Primary endpoint: Urinary output per hour. Started Mar 2017; status: completed.
02
Drugs
riociguatsildenafil
03
Conditions
congenital arginine vasopressin resistance (cAVP-R)
Beyond the preview
Go deeper on 2016-001591-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001591-30.